-
Ami Organics receives USFDA approval for its API manufacturing facility
The US Food and Drug Administration (USFDA) has granted Ami Organics Limited approval for its Active Pharmaceutical Ingredient (API) manufacturing facility located at Sarigam, Gujarat, India. This approval enables Ami Organics to manufacture and supply APIs to the US market, which is the world's largest market for pharmaceuticals.
-
Ami Organics launches new product line of advanced pharmaceutical intermediates
Ami Organics Limited has launched a new product line of advanced pharmaceutical intermediates (APIs). These new products are designed to meet the growing demand for high-quality, cost-effective APIs in the global pharmaceutical industry.
-
Ami Organics signs long-term supply agreement with leading global pharmaceutical company
Ami Organics Limited has signed a long-term supply agreement with a leading global pharmaceutical company. Under the terms of the agreement, Ami Organics will supply the pharmaceutical company with a range of APIs.
-
Ami Organics Limited announces Q3 FY23 results
Ami Organics Limited, a leading manufacturer of specialty chemicals, has announced its financial results for the third quarter ended December 31, 2022.
The company reported a consolidated revenue of Rs. 340.34 crore for Q3 FY23, representing a growth of 23.5% compared to Rs. 275.85 crore in Q3 FY22.
-
Ami Organics Limited receives US FDA approval for manufacturing facility
Ami Organics Limited, a leading manufacturer of specialty chemicals, has received US FDA approval for its manufacturing facility located at Ankleshwar, Gujarat, India.
The approval enables Ami Organics to manufacture and supply a range of APIs, intermediates, and finished dosage forms for the US market.
-
Ami Organics Announces Acquisition of Two Entities
Expanding Presence in High-Growth Specialty Chemical Segments
-
Ami Organics Launches New Production Facility in Gujarat
Increasing Capacity to Meet Growing Global Demand
-
Ami Organics Reports Strong Financial Results for Q3 FY23
Revenue and Profit After Tax Grow Significantly
-
Ami Organics Receives US FDA Approval for its API Manufacturing Facility
Expanding Global Footprint and Compliance
-
Ami Organics Enters into a Joint Venture with a Leading European Pharmaceutical Company
Strengthening International Collaborations
-
Ami Organics gets USFDA nod for Nintedanib API facility
The company had filed an abbreviated new drug application (ANDA) seeking final approval of Nintedanib API from the US health regulator in November 2022
-
Ami Organics gets US FDA nod for Nintedanib API facility
Ami Organics has received US Food and Drug Administration (US FDA) approval for its Nintedanib API manufacturing facility in Gujarat, India.
-
Ami Organics Consolidated December 2022 Net Sales at Rs 186.57 crore, up 7.4% Y-o-Y
The company had posted a net sales of Rs 173.84 crore in the corresponding quarter of the previous fiscal year.
-
Ami Organics Standalone December 2022 Net Sales at Rs 186.57 crore, up 7.4% Y-o-Y
The company had posted a net sales of Rs 173.84 crore in the corresponding quarter of the previous fiscal year.
-
Ami Organics Consolidated Profit jumps 14% to Rs 33 cr in Q3
Ami Organics consolidated profit after tax (PAT) jumped 14 per cent to Rs 33.02 crore in the third quarter ended December 31, 2022, on account of higher revenue.
-
Ami Organics receives USFDA EIR for API manufacturing plant at Ankleshwar
Ami Organics Limited announced that it has recently received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its API manufacturing plant located at Ankleshwar, Gujarat, India.
-
Ami Organics Granted Six New Drug Master Files (DMFs) By USFDA
Ami Organics Limited announced that the US Food & Drug Administration (USFDA) has granted six new Drug Master Files (DMFs) to the Company for its portfolio of APIs.
-
Ami Organics receives USFDA EIR for API manufacturing plant at Sarigam
Ami Organics Limited, a leading manufacturer of specialty chemicals and pharmaceuticals, has recently received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its API manufacturing plant located at Sarigam, Gujarat, India.
-
Ami Organics Granted Two New Drug Master Files (DMFs) By USFDA
Ami Organics Limited announced that the US Food & Drug Administration (USFDA) has granted two new Drug Master Files (DMFs) to the Company for its portfolio of APIs.
-
Ami Organics receives CRAMS facility approval from USFDA
Ami Organics Limited, a leading manufacturer of specialty chemicals and pharmaceuticals, has received approval from the United States Food and Drug Administration (USFDA) for its Contract Research and Manufacturing Services (CRAMS) facility located at Ankleshwar, Gujarat, India.
